Literature DB >> 9687260

Immunology. Ways around rejection.

D L Vaux.   

Abstract

Year:  1998        PMID： 9687260     DOI： 10.1038/28067

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  4 in total

1.  Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

Authors:  D B Chappell; T Z Zaks; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

2.  Sources of error in the retracted scientific literature.

Authors:  Arturo Casadevall; R Grant Steen; Ferric C Fang
Journal:  FASEB J       Date:  2014-06-13       Impact factor: 5.191

3.  A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.

Authors:  Haley E Ramsey; Melissa A Fischer; Taekyu Lee; Agnieszka E Gorska; Maria Pia Arrate; Londa Fuller; Kelli L Boyd; Stephen A Strickland; John Sensintaffar; Leah J Hogdal; Gregory D Ayers; Edward T Olejniczak; Stephen W Fesik; Michael R Savona
Journal:  Cancer Discov       Date:  2018-09-05       Impact factor: 39.397

4.  Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia.

Authors:  Jayna J Mistry; Charlotte Hellmich; Amelia Lambert; Jamie A Moore; Aisha Jibril; Angela Collins; Kristian M Bowles; Stuart A Rushworth
Journal:  Biomark Res       Date:  2021-05-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.